TMDX Transmedics

Filed: 28 May 21, 4:05pm












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2021



TransMedics Group, Inc.

(Exact name of Registrant as Specified in Its Charter)




Massachusetts 001-38891 83-2181531

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

200 Minuteman Road

Andover, Massachusetts 01810

(Address of Principal Executive Offices, and Zip Code)

(978) 552-0900

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange

on which registered

Common Stock, no par value per share TMDX 

The Nasdaq Stock Market LLC

(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2021, at the 2021 Annual Meeting of Shareholders of TransMedics Group, Inc. (the “Company”), the shareholders of the Company voted on the following proposals:

Proposal One: The shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines and David Weill, M.D. as directors, each to serve on the board of directors of the Company until the 2022 annual meeting of the Company’s shareholders to be held in 2022 or until his successor is duly elected and qualified in accordance with our restated articles of organization and amended and restated bylaws, or his earlier death, resignation or removal, based on the following votes:


Director Nominee  For   Withheld   Broker Non-Votes 

Waleed H. Hassanein, M.D

   15,268,356    45,533    4,550,143 

James R. Tobin

   11,757,724    3,556,165    4,550,143 

Edward M. Basile

   13,783,458    1,530,431    4,550,143 

Thomas J. Gunderson

   11,761,418    3,552,471    4,550,143 

Edwin M. Kania

   15,234,966    78,923    4,550,143 

Stephanie Lovell

   15,293,682    20,207    4,550,143 

Merilee Raines

   15,239,563    74,326    4,550,143 

David Weill, M.D.

   11,761,305    3,552,584    4,550,143 

Proposal Two: The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2021, based on the following votes:







19,751,586 110,283 2,163


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  TransMedics Group, Inc.
Date: May 28, 2021  By: 

/s/ Stephen Gordon

   Stephen Gordon
   Chief Financial Officer, Treasurer and Secretary